started · updated
Sildenafil shown to curb cancer metastasis in preclinical studies
Researchers from Israel's Weizmann Institute of Science and the U.S. National Cancer Institute investigated the PDE5‑inhibitor sildenafil for its impact on cancer spread. The drug was found to alter cholesterol handling inside lysosomes, limiting cholesterol availability for tumor cells and impairing their ability to migrate. In cell cultures and mouse models of breast, lung, colon and prostate cancers, sildenafil markedly reduced cell movement and the formation of metastases, while having a smaller effect on primary tumor size. When combined with statins, which lower cholesterol synthesis, the anti‑metastatic effect was further enhanced. Analysis of health records from about five million Israeli Clalit Health Service members—including roughly 40,000 cancer patients—showed that those who had taken sildenafil, often for erectile dysfunction, exhibited better survival, especially when also using statins. The authors stress that these findings are preliminary; clinical trials are required to determine safety, effective dosing and real therapeutic benefit in humans.
Entities
Clalit Health Services · National Cancer Institute · Sildenafil · Statins · Weizmann Institute of Science